Former CoLucid CEO Thomas P. Mathers joins Pappas Capital as Partner
RESEARCH TRIANGLE PARK, N.C., April 10, 2018 — Pappas Capital announced today that Thomas P. “Tom” Mathers has joined the firm as a partner. Mathers previously served as CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD), a Pappas Capital portfolio company that was acquired in early 2017 by Eli Lilly & Company for nearly $1 billion. Mathers’ initial mandate will be to spearhead the formation of a new biopharmaceutical company that is expected to be backed by Pappas and other venture capital investors. In addition to launching the new company, he will source new deals, assist in evaluating prospective investment opportunities and provide expertise and oversight to Pappas portfolio companies. He will be based in Boston.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.